Eli Lilly and Company $LLY Shares Bought by Silicon Valley Capital Partners

Key Points

• Silicon Valley Capital Partners increased its holdings in Eli Lilly and Company by 33.4% in the 1st quarter, owning 16,131 shares worth approximately $13.27 million.
• Eli Lilly reported $6.31 EPS for the most recent quarter, exceeding analyst estimates and showing a 37.6% year-over-year revenue increase to $15.56 billion.
• The company's stock has a consensus rating of "Moderate Buy" with a target price averaging $950.17 based on recent analyst upgrades and downgrades.

Silicon Valley Capital Partners grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 33.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,131 shares of the company's stock after buying an additional 4,040 shares during the quarter. Eli Lilly and Company accounts for 1.7% of Silicon Valley Capital Partners' investment portfolio, making the stock its 17th largest position. Silicon Valley Capital Partners' holdings in Eli Lilly and Company were worth $13,268,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Strs Ohio purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $266,878,000. GK Wealth Management LLC increased its position in shares of Eli Lilly and Company by 39.7% in the first quarter. GK Wealth Management LLC now owns 633 shares of the company's stock valued at $523,000 after buying an additional 180 shares in the last quarter. Ellsworth Advisors LLC increased its position in shares of Eli Lilly and Company by 5.9% in the first quarter. Ellsworth Advisors LLC now owns 2,332 shares of the company's stock valued at $1,926,000 after buying an additional 130 shares in the last quarter. Jacobi Capital Management LLC increased its position in shares of Eli Lilly and Company by 0.3% during the first quarter. Jacobi Capital Management LLC now owns 13,770 shares of the company's stock worth $11,372,000 after purchasing an additional 38 shares in the last quarter. Finally, Carderock Capital Management Inc. increased its position in shares of Eli Lilly and Company by 16.5% during the first quarter. Carderock Capital Management Inc. now owns 9,460 shares of the company's stock worth $7,813,000 after purchasing an additional 1,337 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft decreased their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Wall Street Zen raised Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and raised their price target for the company from $675.00 to $700.00 in a report on Wednesday, August 27th. DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Finally, Morgan Stanley reissued an "overweight" rating and set a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $941.35.

Insider Transactions at Eli Lilly and Company

In related news, Director Jamere Jackson bought 200 shares of the stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the acquisition, the director directly owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock valued at $2,894,841 over the last 90 days. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Down 0.2%

Shares of LLY traded down $1.38 during midday trading on Friday, reaching $754.90. 2,195,977 shares of the company were exchanged, compared to its average volume of 3,737,676. The stock has a 50-day moving average price of $741.03 and a 200-day moving average price of $777.36. The company has a market cap of $714.48 billion, a price-to-earnings ratio of 49.34, a P/E/G ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $942.35. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the previous year, the firm posted $3.92 earnings per share. The firm's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Eli Lilly and Company's payout ratio is currently 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.